ARTICLE | Clinical News

Bepotastine besilate nasal spray: Preliminary Phase I/II data

October 25, 2010 7:00 AM UTC

Preliminary data from a double-blind, Canadian Phase I/II trial in 82 patients exposed on multiple occasions to high aerosol concentrations of a common seasonal allergen to which they were sensitive showed that mid- and high-dose bepotastine nasal spray given twice daily significantly reduced instantaneous and reflective total nasal symptoms vs. placebo. Bepotastine also significantly reduced individual nasal symptoms vs. placebo, with the most rapid improvements observed in sneezing and nasal itching. Bepotastine was well tolerated with no serious adverse events reported. ...